Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Respirol. Jul 28, 2015; 5(2): 93-101
Published online Jul 28, 2015. doi: 10.5320/wjr.v5.i2.93
Collagen vascular disease-associated interstitial lung disease
Christine L Vigeland, Maureen R Horton
Christine L Vigeland, Maureen R Horton, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
Author contributions: Vigeland CL and Horton MR contributed equally to this work.
Supported by the Osborne Family Research Fund.
Conflict-of-interest statement: Dr. Christine L Vigeland is an employee of the Johns Hopkins University School of Medicine. Dr. Maureen R Horton is an employee of the Johns Hopkins University School of Medicine and has received research funding from NIH, FAMRI, American Asthma Foundation, Hoffman-Roche, and InterMune.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Maureen R Horton, MD, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Fifth Floor, Baltimore, MD 21205, United States. mhorton2@jhmi.edu
Telephone: +1-410-6145445 Fax: +1-410-9550299
Received: October 20, 2014
Peer-review started: October 21, 2014
First decision: November 27, 2014
Revised: December 19, 2014
Accepted: March 4, 2015
Article in press: March 5, 2015
Published online: July 28, 2015
Abstract

Interstitial lung disease (ILD) is an important manifestation of collagen vascular diseases. It is a common feature of scleroderma, and also occurs in dermatomyositis and polymyositis, mixed connective tissue disease, Sjogren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, and Antineutrophil cytoplasmic antibody-associated vasculitis. When present, it is associated with increased morbidity and mortality, thus making early diagnosis important. In fact, in many patients, ILD may be the first manifestation of a collagen vascular disease. The most common symptoms are cough and dyspnea. The diagnosis is made based on pulmonary function tests showing restrictive lung disease and impaired oxygen diffusion and chest imaging showing ground glass infiltrates, interstitial thickening, and/or fibrosis. The most common histologic finding on lung biopsy is non-specific interstitial pneumonia, though organizing pneumonia and usual interstitial pneumonia may also be seen. Treatment is focused on addressing the underlying collagen vascular disease with immunosuppression, either with corticosteroids or a steroid-sparing agent such as cyclophosphamide, azathioprine, or mycophenolate, although the optimal agent and duration of therapy is not known. There are few clinical trials to guide therapy that focus specifically on the progression of ILD. The exception is in the case of scleroderma-associated ILD, where cyclophosphamide has been shown to be effective.

Keywords: Interstitial lung disease, Collagen vascular disease, Connective tissue disease, Rheumatoid arthritis, Scleroderma, Myositis, Sjogren’s syndrome, Systemic lupus erythematosus, Antineutrophil cytoplasmic antibody-associated vasculitis, Mixed connective tissue disease

Core tip: Interstitial lung disease (ILD) is a significant manifestation of collagen vascular diseases due to its association with increased morbidity and mortality. Thus it is important for clinicians to consider and be able to recognize collagen vascular disease-associated ILD and initiate appropriate treatment. This review will discuss the clinical features, histologic findings, and treatment options of collagen vascular disease-associated ILD.